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Copyright © 200? JCBN Summary Dietary conjugated linoleic acid (CLA) has been reported to exhibit a number of
therapeutic effects in animal models and patients, such as anti-hypertensive, anti-hyperlipidemic,
anti-arteriosclerotic, anti-carcinogenic, and anti-diabetic effects. However, the underlying
mechanism is not well-characterized. In the present study, the effects of cis(c)9, trans(t)11-CLA
on the differentiation of mouse 3T3-L1 preadipocytes into mature adipocytes were examined.
Treatment with c9, t11-CLA in the presence of insulin, dexamethasone, and 3-isobutyl-1-
methyl-xanthine (differentiation cocktail) significantly stimulated the accumulation of
triacylglycerol. The microscopic observation of cells stained by Oil Red O demonstrated that
c9, t11-CLA increases the amount and proportion of small mature adipocytes secreting
adiponectin, a benign adipocytokine, when compared to the differentiation cocktail alone.
Furthermore, c9, t11-CLA increased bioactive peroxisome proliferator-activated receptor γ
(PPARγ) levels in a nuclear extract of 3T3-L1 cells, suggesting the enhancing effect of this fatty
acid on the nuclear transmission of PPARγ, a master regulator of adipocyte differentiation, in
3T3-L1 cells. These results suggest that the therapeutic effects of c9, t11-CLA on lifestyle-
related diseases are partially due to the enhanced formation of small adipocytes from
preadipocytes via PPARγ stimulation.
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lifestyle-related diseases
Introduction
Conjugated linoleic acid (CLA) is the collective acronym
for combinations of positional and geometric isomers of
linoleic acid that exist naturally in dairy products and meat.
It is produced in ruminant animals via the biohydrogenation
of polyunsaturated fatty acids as well as during the mechan-
ical processing of dairy products [1,  2]. CLA has been
reported to exhibit a number of physiological effects in
animal models and patients, such as anti-hypertensive [3],
anti-hyperlipidemic [4], anti-arteriosclerotic [5], anti-
carcinogenic [6], and anti-diabetic [7] effects. However,
the underlying mechanism behind the effects of CLA is not
fully understood.
One of the common backgrounds of hypertension, hyper-
lipidemia, carcinogenesis, and diabetes is thought to be
obesity. Adipocyte precursor cells (i.e., preadipocytes) are
present throughout life [8]. Accordingly, obesity may be
partially mediated by stimulating the differentiation of
preadipocytes into adipocytes or by increasing fat accumula-
tion in the differentiated adipocytes [9]. Furthermore,S. Sakuma et al.
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adipose tissue has recently been identified as an endocrine
organ that secretes various kinds of bioactive molecule
called adipocytokines. Of these, tumor necrosis factor-α
(TNF-α), which increases in the obese state and is expressed
in enlarged adipocytes, is implicated in various metabolic
disorders, whereas adiponectin, which is expressed in
small adipocytes, is considered to protect against diabetes,
atherosclerosis, etc. [10,  11]. Such enlarged and small
adipocytes have been shown to be generated by differentia-
tion from preadipocytes in vivo [10, 11]. Murine 3T3-L1
preadipocytes have been frequently used to study the
differentiation of preadipocytes in vitro [12–14].
In the present study, we examined the effects of cis(c)9,
trans(t)11-CLA, which is present at high levels in dairy
products [15–17], on the differentiation of 3T3-L1 preadipo-
cytes into adipocytes.
Materials and Methods
Materials
Mouse 3T3-L1 preadipocytes were obtained from the
European Collection of Cell Cultures, Wiltshire, UK. c9,
t11-CLA, and the peroxisome proliferator-activated receptor
γ (PPARγ) Transcription Factor Assay kit were purchased
from Cayman Chemical Co., Ann Arbor, MI. Dulbecco’s
modified Eagle’s medium (DMEM), dexamethasone, 3-
isobutyl-1-methyl-xanthine (IBMX), and protease inhibitor
cocktail were obtained from Sigma Chemical Co., St.
Louis, MO. Penicillin-streptomycin was purchased from
Invitrogen, Life Technologies, Carlsbad, CA. Fetal bovine
serum (FBS) was purchased from Nichirei Biosciences Inc.,
Tokyo, Japan. Triglyceride E-test Wako, 4% formaldehyde-
phosphate buffer (pH 7.4), and Oil Red O dye were obtained
from Wako Pure Chemical Industries, Limited, Osaka,
Japan. GW9962 (2-chloro-5-nitrobenzanilide) was purchased
from Merck Ltd., Darmstadt, Germany. All other reagents
were of analytical grade.
Cell culture
3T3-L1 preadipocytes were cultured at 37°C in a
humidified atmosphere of 5% CO2/95% air. The cells were
maintained in growth medium containing the following:
DMEM with 10% FBS and 1% penicillin-streptomycin.
Differentiation was induced according to the protocol
enclosed with the 3T3-L1 preadipocytes from the European
Collection of Cell Cultures: differentiation of the cells was
initiated 2 days after confluence for 3 days in growth
medium containing 0.25 µM dexamethasone, 0.5 mM IBMX,
and 1 μg/ml insulin. This was followed by 2 days in growth
medium containing 1 µg/ml insulin. Thereafter, the cells were
cultured in the growth medium for 2 days.
Treatment with c9, t11-CLA
c9, t11-CLA was prepared in Me2SO and added to the
medium from day-3 (time of addition of dexamethasone,
IBMX, and insulin) to day-9 (end point of the experiment).
The Me2SO concentration was maintained up to 0.25% of
the total volume, and preliminary experiments demonstrated
no significant effects of 0.25% Me2SO on cell differentiation.
Oil Red O staining
Cells were fixed with 4% formaldehyde-phosphate buffer
(pH 7.4) for 1 h, rinsed with water, and stained with 0.3%
Oil Red O dye for 1 h. After washing again with water,
cells were visually monitored by microscopic observation
(10 × 10-fold or 10 × 20-fold).
Measurement of cell number and size
The 3T3-L1 cells stained with Oil Red O dye as
mentioned above were used for measurement of cell number
and size. The sizes of adipocytes were determined by tracing
the diameters of the cells within 1,300 mm2 of the micro-
scopic pictures using a soft ware (DP2-BSW, OLYMPUS
Corporation, Tokyo, Japan).
Measurement of triacylglycerol (TG)
The cells were harvested by scraping from the culture
dishes into lysis buffer [1% Triton-100, 150 mM NaCl,
4 mM EDTA, and 20 mM Tris-HCl (pH 7.4) containing
protease inhibitor cocktail] and lysed completely using a
horn-type sonicator. The amount of TG, an index of lipid
accumulation, was quantitatively measured using a
Triglyceride E-test Wako kit following normalization by
protein amounts and expressed as TG contents (μg/mg
protein).
Measurement of TNF-α and adiponectin
After incubation, TNF-α and adiponectin in the medium
were measured using a Quantikine mouse TNF-α/TNFSF1A
kit (R&D systems, Inc., Minneapolis, MN) and Mouse/rat
adiponectin ELISA kit (Otsuka Pharmaceutical Co., Ltd.,
Tokyo, Japan), respectively.
Measurement of nuclear bioactive PPARγ
After incubation, 3T3-L1 cells were scraped, and the
nuclear fraction was separated using the Nuclear Extraction
kit (Marligen Biosciences Inc., Rockville, MD). Bioactive
PPARγ in the nucleus was measured using the PPARγ
Transcription Factor Assay kit. A specific double stranded
DNA (dsDNA) sequence containing the peroxisome pro-
liferator response element (PPRE) was immobilized onto
the bottom of wells of a 96 well plate. PPARs contained in a
nuclear extract, bound specifically to the PPRE. PPARγ was
detected by addition of specific primary antibody directed
against PPARγ. A secondary antibody conjugated to horse-Conjugated Linoleic Acid and Adipocyte Differentiation
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Fig. 1. Alterations in TG contents (A) and Oil Red O staining (B) of 3T3-L1 adipocytes treated with c9, t11-CLA. The differentiation
of 3T3-L1 preadipocytes was initiated 2 days after confluence for 3 days in growth medium containing 0.25 μM
dexamethasone, 0.5 mM IBMX, and 1 μg/ml insulin. This was followed by 2 days in growth medium containing 1 μg/ml
insulin. Thereafter, the cells were cultured in the growth medium for 2 days. c9, t11-CLA was added to the medium from day-3
(time of addition of dexamethasone, IBMX, and insulin) to day-9 (end point of the experiment). (A): The treated cells were
lysed with lysis buffer, and the TG contents were measured using a Triglyceride E-test Wako kit. The data represent the
means ± SE. of four experiments. *p<0.05 vs 0 μM. (B): The treated cells were fixed in 4% formaldehyde-phosphate buffer and
stained with 0.3% Oil Red O dye. TG, triacylglycerol; IBMX, 3-isobutyl-1-methyl-xanthine.
Fig. 2. Microscopic observations of Oil Red O staining of 3T3-L1 cells treated with c9, t11-CLA. The differentiation of 3T3-L1
preadipocytes was initiated 2 days after confluence for 3 days in growth medium containing 0.25 μM dexamethasone, 0.5 mM
IBMX, and 1 μg/ml insulin. This was followed by 2 days in growth medium containing 1 μg/ml insulin. Thereafter, the cells
were cultured in the growth medium for 2 days. c9, t11-CLA (100 μM) was added to the medium from day-3 (time of addition
of dexamethasone, IBMX, and insulin) to day-9 (end point of the experiment). The treated cells were fixed in 4%
formaldehyde-phosphate buffer and stained with 0.3% Oil Red O dye. IBMX, 3-isobutyl-1-methyl-xanthine.S. Sakuma et al.
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Fig. 3. Alterations in the cell number (A) and size (B) of c9, t11-CLA-treated 3T3-L1 adipocytes. The differentiation of 3T3-L1 pread-
ipocytes was initiated 2 days after confluence for 3 days in growth medium containing 0.25 μM dexamethasone, 0.5 mM
IBMX, and 1 μg/ml insulin. This was followed by 2 days in growth medium containing 1 μg/ml insulin. Thereafter, the cells
were cultured in the growth medium for 2 days. c9, t11-CLA (100 μM) was added to the medium from day-3 (time of addition
of dexamethasone, IBMX, and insulin) to day-9 (end point of the experiment). The treated cells were fixed in 4%
formaldehyde-phosphate buffer and stained with 0.3% Oil Red O dye. Within 1,300 mm2 of the microscopic pictures, the total
amount (A) and number of cells less than 29 μm, from 30 to 45 μm, or more than 46 μm (B) of the Oil Red O-stained cells in
the presence or absence of c9, t11-CLA were assessed. The data represent the means ± SE. from four experiments. *p<0.01 vs
Control. IBMX, 3-isobutyl-1-methyl-xanthine.
Fig. 4. Changes in the production of TNF-α (A) and adiponectin (B) in 3T3-L1 adipocytes treated with c9, t11-CLA. The differentia-
tion of 3T3-L1 preadipocytes was initiated 2 days after confluence for 3 days in growth medium containing 0.25 μM
dexamethasone, 0.5 mM IBMX, and 1 μg/ml insulin. This was followed by 2 days in growth medium containing 1 μg/ml
insulin. Thereafter, the cells were cultured in the growth medium for 2 days. c9, t11-CLA (100 μM) was added to the medium
from day-3 (time of addition of dexamethasone, IBMX, and insulin) to day-9 (end point of the experiment). TNF-α (A) and
adiponectin (B) in the medium were measured using a Quantikine mouse TNF-α/TNFSF1A kit and Mouse/rat adiponectin
ELISA kit, respectively. The data represent the means ± SE. from four experiments. *p<0.01 vs Control. IBMX, 3-isobutyl-1-
methyl-xanthine; TNF-α, tumor necrosis factor-α.Conjugated Linoleic Acid and Adipocyte Differentiation
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radish peroxidase was added to provide a sensitive coloro-
metric readout at 450 nm.
Statistical analysis
Results are the means ± SE. The significance of differ-
ences between two groups was assessed employing the t test,
and differences between multiple groups were assessed by
one-way analysis of variance (ANOVA), followed by
Scheffe’s multiple range test. p values less than 0.05 were
considered significant.
Results and Discussion
Fig. 1A shows the effect of c9, t11-CLA on the accumula-
tion of TG, a marker of lipid accumulation, during the
differentiation of 3T3-L1 preadipocytes into adipocytes. At
concentrations of 10, 50, and 100 μM, c9, t11-CLA dose-
dependently enhanced the TG contents (100 μM c9, t11-
CLA, 1.31-fold). As shown in Fig. 1B, the cells treated
with c9, t11-CLA (100 μM) were dyed red with Oil Red O
more deeply than the control. These results demonstrated
that c9, t11-CLA can be a stimulator of TG accumulation in
adipocytes.
Next, 3T3-L1 adipocytes with or without c9, t11-CLA
(100 μM) in the presence of a differentiation cocktail were
visualized by Oil Red O staining, and the morphology of
cells was observed microscopically (10 × 10-fold, 10 × 20-
fold) (Fig. 2). c9, t11-CLA-treated cells contained more and
smaller adipocytes with lipid filling compared to the control.
Within 1,300 mm2 of the microscopic pictures, the c9, t11-
CLA (100 μM)-treated group contained about 3.2-fold more
Oil Red O-stained cells than the control group (Fig. 3A).
About 71% of the c9, t11-CLA (100 μM)-treated cells were
less than 29 μm in size, whereas about 56% of the control
group comprised cells more than 46 μm in size (Fig. 3B).
These results indicate that c9, t11-CLA increases the number
of small adipocytes during the differentiation of 3T3-L1
cells.
It has been reported that adipocyte size is an important
determinant of adipocytokine secretion [10, 11]; an increasing
adipocyte size results in a shift toward the dominance of pro-
inflammatory adipocytokines like TNF-α, and a decrease
in the size toward the dominance of anti-inflammatory
adipocytokines like adiponectin. Fig. 4 illustrates the effects
of c9, t11-CLA on the secretion of TNF-α and adiponectin
from adipocytes after differentiation. c9, t11-CLA (100 μM)
Fig. 5. The effects of the PPARγ agonist rosiglitazone and antagonist GW9662 on the TG contents (A) and Oil Red O staining (B) of
3T3-L1 adipocytes. The differentiation of 3T3-L1 preadipocytes was initiated 2 days after confluence for 3 days in growth
medium containing 0.25 μM dexamethasone, 0.5 mM IBMX, and 1 μg/ml insulin. This was followed by 2 days in growth
medium containing 1 μg/ml insulin. Thereafter, the cells were cultured in the growth medium for 2 days. Rosiglitazone (1 μM)
or GW9662 (5 μM) was added to the medium from day-3 (time of addition of dexamethasone, IBMX, and insulin) to day-9
(end point of the experiment). (A): The treated cells were lysed with lysis buffer, and the TG contents were measured using a
Triglyceride E-test Wako kit. The data represent the means ± SE. from four experiments. *p<0.01 vs Control. (B): The treated
cells were fixed in 4% formaldehyde-phosphate buffer and stained with 0.3% Oil Red O dye. PPARγ, peroxisome proliferator-
activated receptor γ; IBMX, 3-isobutyl-1-methyl-xanthine; TG, triacylglycerol.S. Sakuma et al.
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showed no significant effect on the secretion of TNF-α,
whereas it significantly increased the secretion of adiponectin
(2.7-fold), when compared to the control. Thus, it is thought
that c9, t11-CLA enhances adiponectin secretion from
adipocytes by increasing the emergence of small-sized cells.
PPARγ is known as a master regulator of adipocyte
differentiation [9,  10,  18,  19]. Yamauchi et al. [ 10] and
Okuno  et al. [ 19] have shown that thiazolidinediones,
rosiglitazone and troglitazone, activate PPARγ, which is
expressed primarily in adipose tissues. They suggested that
the primary action of thiazolidinediones is to stimulate the
accumulation of TG and the number of small adipocytes
preferentially secreting adiponectin, in white adipose
tissues, presumably via PPARγ. Therefore, we compared
the effect of c9, t11-CLA with rosiglitazone on activating
PPARγ. Rosiglitazone (1 μM) increased the TG content of
3T3-L1 cells, and GW9962 (5 μM), a PPARγ antagonist
inhibited it (Fig. 4A). Rosiglitazone also increased small
adipocytes when compared to the control (Fig. 4B). The
addition of c9, t11-CLA (100 μM) significantly increased
bioactive PPARγ in the nucleus of 3T3-L1 cells to the same
extent as rosiglitazone (1 μM). These data indicate that
c9, t11-CLA stimulates TG accumulation and the number of
small adipocytes preferentially secreting adiponectin, in
3T3-L1 cells, through an increase in nuclear PPARγ.
To date, the effect of CLA on TG accumulation and
adipocyte differentiation has been controversial. For example,
Satory and Smith [20] reported that CLA isomers (41% c9,
t11 isomer; 44% t10, c12 isomer; and 15% other isomers)
increase adipogenesis and TG accumulation during the
differentiation period of 3T3-L1 cells. In contrast, others
reported that treating 3T3-L1 preadipocytes with t10, c12-
CLA during the differentiation period reduced TG accumu-
lation [21, 22]. Similarly, Choi et al. [18] reported that a
mixture of c9, t11 and t10, c12-CLA attenuated differentia-
tion marker genes such as adipocyte fatty acid-binding
protein (aP2) and PPARγ in 3T3-L1 adipocytes, whereas
t10, c12-CLA alone did not affect the expression levels of
these genes. Under the present assay conditions, t10, c12-
CLA up to 100 μM did not have any significant effect on the
accumulation of TG during the differentiation of 3T3-L1
preadipocytes into adipocytes (data not shown). The
difference between the results of the present study and
previous observations [18, 21, 22] may be related to the
way of the CLA treatment; in the experiments undertaken
by Choi et al. [18], Brown et al. [21] and Evans et al. [22],
CLA isomers were complex to fatty acid-free serum
albumin, and added to the cultures on day 1 of the differen-
tiation. On the other hand, in the present study, c9, t11-CLA
was prepared in Me2SO and added to the medium at the
same time as the previous reports. Satory and Smith [20]
also used ethanol as a solvent for the CLA isomers. Thus,
the direct interaction of c9, t11-CLA with 3T3-L1 cells
may promote the signal transduction for the differentiation.
Fig. 6. Alterations in bioactive PPARγ in the nuclear extract of 3T3-L1 cells treated with c9, t11-CLA. The differentiation of 3T3-L1
preadipocytes was initiated 2 days after confluence for 3 days in growth medium containing 0.25 μM dexamethasone, 0.5 mM
IBMX, and 1 μg/ml insulin. This was followed by 2 days in growth medium containing 1 μg/ml insulin. Thereafter, the cells
were cultured in the growth medium for 2 days. Rosiglitazone (1 μM) or c9, t11-CLA (100 μM) was added to the medium from
day-3 (time of addition of dexamethasone, IBMX, and insulin) to day-9 (end point of the experiment). Bioactive PPARγ in the
nuclear extract from treated cells was measured using the PPARγ Transcription Factor Assay kit. The data represent the
means ± SE. from five experiments. *p<0.05 vs Control. PPARγ, peroxisome proliferator-activated receptor γ; IBMX, 3-isobu-
tyl-1-methyl-xanthine.Conjugated Linoleic Acid and Adipocyte Differentiation
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Although a fraction of blood circulating and cell-constructed
c9, t11-CLA is thought to exist in the form of the free CLA
and to affect the cell functions, further studies are needed to
clarify the significance of the present findings.
In conclusion, the present study is the first to show that c9,
t11-CLA can be a stimulator of adiponectin secretion by
forming benign small-sized adipocytes, and suggests that
this effect may partially explain the anti-hypertensive, anti-
hyperlipidemic, anti-arteriosclerotic, anti-carcinogenic, and
anti-diabetic effects mediated by CLAs. At least, the present
findings may provide new information to extend the ongoing
debate as to the mechanisms through which CLAs play
functional roles both physiologically and pharmacologically
in animal and human bodies.
Abbreviations
CLA, conjugated linoleic acid; PPARγ, peroxisome
proliferator-activated receptor γ; TG, triacylglycerol; TNF-
α, tumor necrosis factor-α; DMEM, Dulbecco’s modified
Eagle’s medium; IBMX, 3-isobutyl-1-methyl-xanthine; FBS,
fetal bovine serum.
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